Holen Sie sich die Stockscreener-App
10.03
1.18%
-0.12
Handel nachbörslich:
10.12
0.09
+0.90%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Research Analysts Issue Forecasts for SPRY Q3 Earnings - MarketBeat
Alliancebernstein L.P. Acquires 42,071 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Octagon Capital Advisors LP Takes Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
ARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Trexquant Investment LP - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 1-Year LowTime to Sell? - MarketBeat
Ars Pharmaceuticals Reports Strong Q2 Growth and Global Expansion - MSN
Alyeska Investment Group L.P. Reduces Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Cormorant Asset Management LP Acquires 1,100,000 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Neffy demonstrates positive, real-world data for anaphylaxis - Contemporary Pediatrics
Is ARS Pharmaceuticals Inc. attractive at current valuation2025 Growth vs Value & Fast Entry and Exit Trade Plans - Lancaster City Council
ARS Pharmaceuticals announces real-world evidence on neffy effectiveness - Yahoo Finance
Roth Capital Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis - markets.businessinsider.com
Real-World Evidence Supports Clinical Effectiveness of - GlobeNewswire
89% Success Rate: Revolutionary Nasal Spray neffy Matches Standard Injection for Life-Threatening Allergies - Stock Titan
Published on: 2025-09-08 12:54:11 - beatles.ru
AI Trend Models Suggest Bounce for ARS Pharmaceuticals Inc.2025 Market Trends & AI Driven Stock Price Forecasts - beatles.ru
325,000 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Ardsley Advisory Partners LP - MarketBeat
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA - MSN
What moving averages say about ARS Pharmaceuticals Inc.Weekly Stock Report & Consistent Return Investment Signals - Newser
MPM Bioimpact LLC Makes New $16.52 Million Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Will ARS Pharmaceuticals' (SPRY) Conference Outreach Shape Investor Expectations for neffy's Global Potential? - simplywall.st
Is it too late to sell ARS Pharmaceuticals Inc.July 2025 PostEarnings & AI Driven Stock Price Forecasts - Newser
ARS Pharmaceuticals, Inc. $SPRY Shares Sold by Rafferty Asset Management LLC - MarketBeat
What’s the outlook for ARS Pharmaceuticals Inc.’s sectorQuarterly Market Review & Risk Controlled Stock Pick Alerts - خودرو بانک
Using economic indicators to assess ARS Pharmaceuticals Inc. potentialJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
ARS Pharmaceuticals stock hits 52-week low at 9.97 USD By Investing.com - Investing.com Canada
What is ARS Pharmaceuticals Inc. s debt to equity ratio2025 Sector Review & Growth Focused Investment Plans - خودرو بانک
What drives ARS Pharmaceuticals Inc.’s stock priceTrade Performance Summary & Reliable Price Breakout Signals - خودرو بانک
Key resistance and support levels for ARS Pharmaceuticals Inc.Earnings Growth Summary & Safe Entry Trade Signal Reports - Newser
Price momentum metrics for ARS Pharmaceuticals Inc. explainedJuly 2025 Setups & Expert Curated Trade Setups - Newser
ARS Pharmaceuticals stock hits 52-week low at 9.97 USD - Investing.com
Is ARS Pharmaceuticals Inc. backed by strong institutional buyingEarnings Recap Summary & Daily Technical Stock Forecast Reports - خودرو بانک
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
Intraday pattern recognizer results for ARS Pharmaceuticals Inc.2025 Trade Ideas & Real-Time Stock Price Movement Reports - Newser
Chart overlay techniques for tracking ARS Pharmaceuticals Inc.Global Markets & Real-Time Buy Zone Alerts - Newser
Raymond James Financial Inc. Has $8.89 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Comparing ARS Pharmaceuticals Inc. in custom built stock radarsMarket Risk Report & Risk Managed Investment Strategies - Newser
When is the best time to exit ARS Pharmaceuticals Inc.Portfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is ARS Pharmaceuticals Inc. forming a bottoming basePortfolio Value Summary & Daily Entry Point Alerts - Newser
What recovery options are there for ARS Pharmaceuticals Inc.Trade Performance Summary & Community Verified Watchlist Alerts - Newser
What are the risks of holding ARS Pharmaceuticals Inc.2025 Bull vs Bear & Free Accurate Trade Setup Notifications - خودرو بانک
Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential - Investing.com Nigeria
What are ARS Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - خودرو بانک
What are ARS Pharmaceuticals Inc.’s growth leversJuly 2025 Snapshot & Verified Momentum Stock Watchlist - خودرو بانک
Short Squeeze: How does ARS Pharmaceuticals Inc. compare to its peersWeekly Trade Summary & Breakout Confirmation Trade Signals - خودرو بانک
ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 27% Share Price Plunge Could Signal Some Risk - 富途牛牛
What machine learning models say about ARS Pharmaceuticals Inc.July 2025 Movers & Safe Capital Investment Plans - Newser
Kodai Capital Management LP Acquires Shares of 60,111 ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Using data models to predict ARS Pharmaceuticals Inc. stock movementGap Up & Community Shared Stock Ideas - Newser
Applying Elliott Wave Theory to ARS Pharmaceuticals Inc.Rate Hike & Breakout Confirmation Alerts - Newser
Real time social sentiment graph for ARS Pharmaceuticals Inc.Trend Reversal & Trade Opportunity Analysis - Newser
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):